Tirasemtiv

Drug Profile

Tirasemtiv

Alternative Names: CK-2017357; CK-357

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokinetics
  • Class 2 ring heterocyclic compounds; Alkynes; Imidazolidines; Pyrazines; Small molecules
  • Mechanism of Action Troponin tropomyosin complex stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis
  • Phase II Muscle fatigue; Myasthenia gravis
  • No development reported Spinal muscular atrophy

Most Recent Events

  • 09 Dec 2016 Adverse event data from the phase III VITALITY-ALS trial in Amyotrophic lateral sclerosis released by Cytokinetics
  • 18 Oct 2016 Cytokinetics initiates the phase III extension VIGOR-ALS trial for Amyotrophic lateral sclerosis in USA and Canada (PO) (NCT02936635)
  • 17 Aug 2016 Cytokinetics completes enrolment in the phase III VITALITY-ALS trial in Amyotrophic lateral sclerosis in North America and Europe (NCT02496767)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top